COMPARATIVE EFFICACY OF A SINGLE ORAL DOSE OF ONDANSETRON AND OF BUSPIRONE AGAINST CISPLATIN-INDUCED EMESIS IN CANCER-PATIENTS

被引:14
作者
ALFIERI, AB [1 ]
CUBEDDU, LX [1 ]
机构
[1] CENT UNIV VENEZUELA, SCH PHARM, DEPT PHARMACOL, CARACAS, VENEZUELA
关键词
SEROTONIN; EMESIS; CISPLATIN; BUSPIRONE; ONDANSETRON; SEROTONIN RECEPTORS;
D O I
10.1038/bjc.1995.452
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Buspirone, an agonist of the 5-HT1A subtype of serotonin receptors, has shown antiemetic activity in animal models. However, in cancer patients treated with cisplatin, ondansetron, given either i.v. (one 8-mg dose 30 min after cisplatin) or orally (one 16-mg dose at the end of cisplatin infusion) was superior (P<0.001) to buspirone (60 mg p.o. at the end of cisplatin and 60 mg p.o., 30 min later), in all parameters of antiemetic efficacy. These results are in favour of 5-HT3 receptors, but against the participation of 5-HT1A receptors in acute emesis associated with cisplatin chemotherapy.
引用
收藏
页码:1013 / 1015
页数:3
相关论文
共 15 条
[11]  
MCEVOY GK, 1993, ANDRIRONE, P1432
[12]  
MILANO S, 1992, COLLOQ INSE, V223, P353
[13]   ANTIEMETIC EFFECTS OF SEROTONERGIC 5-HT1A-RECEPTOR AGONISTS IN SUNCUS-MURINUS [J].
OKADA, F ;
TORII, Y ;
SAITO, H ;
MATSUKI, N .
JAPANESE JOURNAL OF PHARMACOLOGY, 1994, 64 (02) :109-114
[14]   COMPARISON OF THE ANTIEMETIC EFFICACY OF DIFFERENT DOSES OF ONDANSETRON, GIVEN AS EITHER A CONTINUOUS INFUSION OR A SINGLE INTRAVENOUS DOSE, IN ACUTE CISPLATIN-INDUCED EMESIS - A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP-STUDY [J].
SEYNAEVE, C ;
SCHULLER, J ;
BUSER, K ;
PORTEDER, H ;
VANBELLE, S ;
SEVELDA, P ;
CHRISTMANN, D ;
SCHMIDT, M ;
KITCHENER, H ;
PAES, D ;
DEMULDER, PHM ;
LUDWIG, H ;
LENZHOFER, R ;
CHATELAIN, C ;
DAUBRESSE, M ;
FOCAN, C ;
HUYS ;
PARIDAENS, R ;
WEYNANTS, P ;
HANSEN, O ;
MATTSON, K ;
VERMORKEN, J ;
WILS, J ;
MAGNUSSON, K ;
ROBINSON, E ;
BRENNER, HJ ;
DICATO, M ;
DIAZRUBIO, E ;
GONZALEZBARON, DM ;
CUNNINGHAM, D ;
MORGAN, D ;
ROBERTS, T ;
BRUNTSCH, U ;
MEINECKE, H ;
OHL, S ;
RAETH, U ;
WESTERHAUSEN, M .
BRITISH JOURNAL OF CANCER, 1992, 66 (01) :192-197
[15]  
WELLS U, 1993, MED SCI SYMP SER, V5, P179